Figure 5.
Summary of previous animal trials to elucidate the processing and releasing of Survivin siRNA incorporated in the RNA nanoparticles
The data is from models of non-small-cell lung,82 breast,30 and prostate30 cancer. RNA nanoparticles harboring Survivin siRNA were loaded into exosomes and decorated with either epidermal growth factor (EGFR) or prostate-specific membrane antigen (PSMA) RNA aptamers and delivered to prostate cancer, triple negative breast cancer (TNBC), and non-small-cell lung cancer (NSCLC) tumors in mice. Repeated administration demonstrated strong tumor inhibition over control nanoparticles. The data in this figure are a summary of previously published work. Inclusion of the previously published animal data follows the journal policy of Molecular Therapy Nucleic Acids, with figure copyright permission from the publishers and original data from the authors.30,81